NAD-brain is a pharmacokinetic study of brain NAD replenishment therapy. We will try to determine the change in the blood NAD-metabolome and cerebral NAD levels, following the administration of oral NAD replenishment therapy (NRT) with the following NAD precursors: NR 600mg x 2 daily, NMN 600mg x 2 daily.
We will measure the levels of cerebral NAD levels change by MRI and blood samples reputedly during the trial. A total of 10 healthy individuals (5 men and 5 women) and 10 individuals with PD (5 men and 5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of NR 600mg x 2, or NMN 600mg x 2. There will be a washout period of 14 days between the periods so total time is 54 days.
This study has completed recruitment and has started in January 2023.